Reported Monday, BioCryst Launches ORLADEYO® In Italy For Hereditary Angioedema Prevention
Author: Benzinga Newsdesk | February 20, 2024 04:48am
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Italian Medicines Agency, Agenzia Italiana del Farmaco (AIFA), has finalized reimbursement and recommended ORLADEYO® (berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older. With this recommendation, HAE patients in Italy now have access to the first oral, once-daily therapy for the routine prevention of recurrent HAE attacks.
Posted In: BCRX